NASDAQ:MBRX

Moleculin Biotech - MBRX Stock Forecast, Price & News

$1.14

-0.03 (-2.16%)

(As of 09/27/2022 02:04 PM ET)

Add

Compare

Today's Range: $0.95
▼
$1.14
50-Day Range: $1.15
▼
$1.90
52-Week Range: $1.02
▼
$3.08

Volume: 2,650 shs
Average Volume: 175,402 shs
Market Capitalization: $32.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Moleculin Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,239.3% Upside
$15.00 Price Target
Short Interest: Healthy
0.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.02) to ($1.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

894th out of 1,071 stocks

Pharmaceutical Preparations Industry

425th out of 531 stocks

3.5

Analyst's Opinion

Consensus Rating
Moleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Moleculin Biotech has a forecasted upside of 1,239.3% from its current price of $1.12.
Amount of Analyst Coverage
Moleculin Biotech has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.56% of the float of Moleculin Biotech has been sold short.
Short Interest Ratio / Days to Cover
Moleculin Biotech has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Moleculin Biotech has recently increased by 59.21%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Moleculin Biotech does not currently pay a dividend.
Dividend Growth
Moleculin Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MBRX.

1.9

News and Social Media Coverage

News Sentiment
Moleculin Biotech has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Moleculin Biotech this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 3 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Moleculin Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Moleculin Biotech is held by insiders.
Percentage Held by Institutions
Only 10.48% of the stock of Moleculin Biotech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Moleculin Biotech are expected to decrease in the coming year, from ($1.02) to ($1.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Moleculin Biotech is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Moleculin Biotech is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Moleculin Biotech has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Moleculin Biotech (NASDAQ:MBRX) Stock

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Stock News Headlines

September 27, 2022 | msn.com

Moleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal Studies

September 27, 2022 | finance.yahoo.com

Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

September 23, 2022 | finance.yahoo.com

Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event

September 23, 2022 | americanbankingnews.com

Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

September 18, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)

September 8, 2022 | finance.yahoo.com

Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

September 7, 2022 | finance.yahoo.com

Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022 | nasdaq.com

Moleculin Biotech Announces Receipt Of Orphan Drug Designation For WP1122 - Quick Facts

August 19, 2022 | finance.yahoo.com

Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

August 16, 2022 | seekingalpha.com

Moleculin Biotech GAAP EPS of -$0.24

August 15, 2022 | finance.yahoo.com

Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update

June 16, 2022 | finance.yahoo.com

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

May 26, 2022 | seekingalpha.com

Moleculin begins human trial of WP1122 to treat COVID-19

May 26, 2022 | msn.com

Moleculin Biotech Doses Healthy Volunteers For Covid-19 In Early-Stage Study Of WP1122

May 26, 2022 | finance.yahoo.com

Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

May 19, 2022 | finance.yahoo.com

Moleculin to Present at the H.C. Wainwright Global Investment Conference

May 12, 2022 | investing.com

Moleculin Biotech Reports Q1 Result

May 12, 2022 | finance.yahoo.com

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

May 5, 2022 | finance.yahoo.com

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

May 4, 2022 | finance.yahoo.com

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

April 21, 2022 | seekingalpha.com

Moleculin cleared to conduct phase 1 study of WP1066 for treatment of recurrent brain tumor

April 21, 2022 | finance.yahoo.com

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

April 21, 2022 | benzinga.com

FDA clears Moleculin's IND application to Conduct Phase 1 Study of WP1066 for Recurrent Malignant Glioma

April 14, 2022 | finance.yahoo.com

Moleculin Announces Corporate Rebranding and Launch of New Website

April 11, 2022 | finance.yahoo.com

/C O R R E C T I O N -- Moleculin Biotech, Inc./

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Company Calendar

Last Earnings: 8/15/2022
Today: 9/27/2022
Next Earnings (Estimated): 11/10/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MBRX
CUSIP: N/A
CIK: 1659617
Web: www.moleculin.com
Phone: (713) 300-5160
Fax: N/A
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +1,221.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.94%
Return on Assets: -28.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.47
Quick Ratio: 10.47

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.76 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 28,610,000
Free Float: 27,549,000
Market Cap: $32.47 million
Optionable: Not Optionable
Beta: 1.77

Key Executives

Mr. Walter V. Klemp (Age 62)
Founder, Chairman, Pres & CEO
Comp: $891.66k

Mr. Jonathan P. Foster CPA (Age 58)
Exec. VP & CFO
Comp: $611.2k

Dr. Donald H. Picker Ph.D. (Age 76)
Chief Scientific Officer
Comp: $479.87k

Dr. Waldemar Priebe Ph.D.
Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board

Dr. Robert C. Shepard FACP (Age 70)
M.D., F.A.C.P., Chief Medical Officer of Annamycin

Dr. John Paul Waymack M.D. (Age 70)
Sc.D., Sr. Chief Medical Officer

Dr. Sandra L. Silberman M.D. (Age 67)
Ph.D., Chief Medical Officer of New Products

Dr. Wolfram C. M. Dempke M.B.A.
M.D., Ph.D., European Chief Medical Officer

Ms. Jacqueline Northcut (Age 60)
Consultant

Mr. Louis Ploth Jr. (Age 68)
Independent Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MBRX Stock - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings or view top-rated stocks.
What is Moleculin Biotech's stock price forecast for 2022?: 1 Wall Street analysts have issued 1-year price objectives for Moleculin Biotech's stock. Their MBRX share price forecasts range from $14.00 to $16.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 1,193.1% from the stock's current price.
View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts.
How have MBRX shares performed in 2022?: Moleculin Biotech's stock was trading at $1.86 on January 1st, 2022. Since then, MBRX shares have decreased by 37.6% and is now trading at $1.16.
View the best growth stocks for 2022 here.
When is Moleculin Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our MBRX earnings forecast.
How were Moleculin Biotech's earnings last quarter?: Moleculin Biotech, Inc. (NASDAQ:MBRX) released its quarterly earnings data on Monday, August, 15th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01.
When did Moleculin Biotech's stock split?: Moleculin Biotech's stock reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).
What is Moleculin Biotech's stock symbol?: Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."
Who are Moleculin Biotech's major shareholders?: Moleculin Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.31%) and Walker Asset Management LLC (0.07%).
View institutional ownership trends.
How do I buy shares of Moleculin Biotech?: Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Moleculin Biotech's stock price today?: One share of MBRX stock can currently be purchased for approximately $1.16.
How much money does Moleculin Biotech make?: Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $33.19 million. The company earns $-15,890,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.
How can I contact Moleculin Biotech?: Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com.

This page (NASDAQ:MBRX) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Moleculin Biotech - MBRX Stock Forecast, Price & News

Moleculin Biotech MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month